Show simple item record

dc.contributor.authorNnamani, Petra O
dc.contributor.authorHansen, Steffi
dc.contributor.authorWindbergs, Maike
dc.contributor.authorLehr, Claus-Michael
dc.date.accessioned2015-01-05T15:52:09Zen
dc.date.available2015-01-05T15:52:09Zen
dc.date.issued2014-12-30en
dc.identifier.citationDevelopment of artemether-loaded nanostructured lipid carrier (NLC) formulation for topical application. 2014, 477 (1-2):208-17 Int J Pharmen
dc.identifier.issn1873-3476en
dc.identifier.pmid25290810en
dc.identifier.doi10.1016/j.ijpharm.2014.10.004en
dc.identifier.urihttp://hdl.handle.net/10033/337849en
dc.description.abstractNLC topical formulation as an alternative to oral and parenteral (IM) delivery of artemether (ART), a poorly water-soluble drug was designed. A Phospholipon 85G-modified Gelucire 43/01 based NLC formulation containing 75% Transcutol was chosen from DSC studies and loaded with gradient concentration of ART (100-750mg). ART-loaded NLCs were stable (-22 to -40mV), polydispersed (0.4-0.7) with d90 size distribution range of 247-530nm without microparticles up to one month of storage. The encapsulation efficiency (EE%) for ART in the NLC was concentration independent as 250mg of ART loading achieved ∼61%. DSC confirmed molecular dispersion of ART due to low matrix crystallinity (0.028J/g). Ex vivo study showed detectable ART amounts after 20h which gradually increased over 48h achieving ∼26% cumulative amount permeated irrespective of the applied dose. This proves that ART permeates excised human epidermis, where the current formulation served as a reservoir to gradually control drug release over an extended period of time. Full thickness skin study therefore may confirm if this is a positive signal to hope for a topical delivery system of ART.
dc.language.isoenen
dc.titleDevelopment of artemether-loaded nanostructured lipid carrier (NLC) formulation for topical application.en
dc.typeArticleen
dc.identifier.journalInternational journal of pharmaceuticsen
refterms.dateFOA2018-06-13T07:46:29Z
html.description.abstractNLC topical formulation as an alternative to oral and parenteral (IM) delivery of artemether (ART), a poorly water-soluble drug was designed. A Phospholipon 85G-modified Gelucire 43/01 based NLC formulation containing 75% Transcutol was chosen from DSC studies and loaded with gradient concentration of ART (100-750mg). ART-loaded NLCs were stable (-22 to -40mV), polydispersed (0.4-0.7) with d90 size distribution range of 247-530nm without microparticles up to one month of storage. The encapsulation efficiency (EE%) for ART in the NLC was concentration independent as 250mg of ART loading achieved ∼61%. DSC confirmed molecular dispersion of ART due to low matrix crystallinity (0.028J/g). Ex vivo study showed detectable ART amounts after 20h which gradually increased over 48h achieving ∼26% cumulative amount permeated irrespective of the applied dose. This proves that ART permeates excised human epidermis, where the current formulation served as a reservoir to gradually control drug release over an extended period of time. Full thickness skin study therefore may confirm if this is a positive signal to hope for a topical delivery system of ART.


Files in this item

Thumbnail
Name:
Publisher version
Thumbnail
Name:
Nnamani et al_final.pdf
Size:
322.2Kb
Format:
PDF
Description:
original manuscript
Thumbnail
Name:
Figures.pdf
Size:
1.783Mb
Format:
PDF
Description:
figures
Thumbnail
Name:
Tables.pdf
Size:
309.0Kb
Format:
PDF
Description:
tables

This item appears in the following Collection(s)

Show simple item record